104 related articles for article (PubMed ID: 183591)
21. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.
Tindall RS; Rollins JA; Phillips JT; Greenlee RG; Wells L; Belendiuk G
N Engl J Med; 1987 Mar; 316(12):719-24. PubMed ID: 3547126
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of methotrexate in myasthenia gravis.
Pasnoor M; He J; Herbelin L; Dimachkie M; Barohn RJ;
Ann N Y Acad Sci; 2012 Dec; 1275(1):23-8. PubMed ID: 23278574
[TBL] [Abstract][Full Text] [Related]
23. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.
Seybold ME; Drachman DB
N Engl J Med; 1974 Jan; 290(2):81-4. PubMed ID: 4808454
[No Abstract] [Full Text] [Related]
24. A clinical therapeutic trial of cyclosporine in myasthenia gravis.
Tindall RS; Phillips JT; Rollins JA; Wells L; Hall K
Ann N Y Acad Sci; 1993 Jun; 681():539-51. PubMed ID: 8357194
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of corticosteroid therapy in patients with myasthenia gravis.
Evoli A; Batocchi AP; Palmisani MT; Lo Monaco M; Tonali P
Eur Neurol; 1992; 32(1):37-43. PubMed ID: 1563453
[TBL] [Abstract][Full Text] [Related]
26. Myasthenia gravis and myasthenic syndromes treated with prednisone.
Kjaer M
Acta Neurol Scand; 1971; 47(4):464-74. PubMed ID: 4330810
[No Abstract] [Full Text] [Related]
27. Steroid therapy of myasthenia gravis.
Vijayan N; Dreyfus PM
West J Med; 1975 Aug; 123(2):130-1. PubMed ID: 170745
[No Abstract] [Full Text] [Related]
28. Factors influencing outcome of prednisone dose reduction in myasthenia gravis.
Miano MA; Bosley TM; Heiman-Patterson TD; Reed J; Sergott RC; Savino PJ; Schatz NJ
Neurology; 1991 Jun; 41(6):919-21. PubMed ID: 2046940
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
[TBL] [Abstract][Full Text] [Related]
30. [Favorable results of plasmapheresis in severe myasthenia gravis].
Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ
Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298
[TBL] [Abstract][Full Text] [Related]
31. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
[TBL] [Abstract][Full Text] [Related]
32. [Myasthenia gravis (3). Corticosteroid therapy of myasthenia gravis].
Matell G; Osterman PO
Lakartidningen; 1978 Oct; 75(41):3667-9. PubMed ID: 692233
[No Abstract] [Full Text] [Related]
33. Long-term corticosteroid treatment of myasthenia gravis.
Johns TR
Ann N Y Acad Sci; 1987; 505():568-83. PubMed ID: 3479938
[No Abstract] [Full Text] [Related]
34. Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs.
Johns TR; Howard FM
Trans Am Neurol Assoc; 1978; 103():278-81. PubMed ID: 229611
[No Abstract] [Full Text] [Related]
35. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
Palace J; Newsom-Davis J; Lecky B
Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
[TBL] [Abstract][Full Text] [Related]
36. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
37. Oral corticosteroids in the treatment of ocular myasthenia gravis.
Fischer KC; Schwartzmann RJ
Neurology; 1974 Aug; 24(8):795-8. PubMed ID: 4858423
[No Abstract] [Full Text] [Related]
38. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.
J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1157-63. PubMed ID: 8229026
[TBL] [Abstract][Full Text] [Related]
39. Stable remissions in myasthenia gravis.
Perez MC; Buot WL; Mercado-Danguilan C; Bagabaldo ZG; Renales LD
Neurology; 1981 Jan; 31(1):32-7. PubMed ID: 7192824
[TBL] [Abstract][Full Text] [Related]
40. [Predictive factors of the response to treatment of myasthenia gravis with prednisone].
Pradas J; Illa I
Neurologia; 1990 Jan; 5(1):11-3. PubMed ID: 2361025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
